ArticleDiscover oncology2025
City scale related to epidermal growth factor receptor mutations status in Chinese non-small cell lung cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aimed to explore the relationship between city scale and epidermal growth factor receptor (EGFR) mutation status in Chinese patients with non-small cell lung cancer (NSCLC).
methodsA retrospective study enrolled NSCLC patients who underwent tissue EGFR mutation testing at Sun Yat-sen University Cancer Center from 2012 to 2017. City scale was categorized according to classifications made by the State Council of China in 2014. Multivariable logistic regression was utilized to determine independent predictors of EGFR mutation status in NSCLC patients.
resultsA total of 4637 NSCLC patients were enrolled in this study. EGFR mutation related to gender, smoking statue, histological type, and city scale. Higher rate of EGFR mutations among patients of super large-sized and very large-sized cities compared to other cities. There was an inverse relationship between city scale and smoking status among patients. Multivariate analysis showed that city scale was not an independent predictor of EGFR mutation.
conclusionsAlthough there is a correlation between the size of a city and the rates of EGFR mutations in Chinese NSCLC patients, city scale does not independently predict these mutation rates. Instead, the variations in EGFR mutation rates could be indirectly related to different levels of urbanization, which may influence smoking behaviors among the populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.